ReviewJournal of inflammation research2026
Targeting Inflammation in Osteoarthritis Pain: A Phenotype-Driven Approach.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is a chronic joint disease marked by the progressive loss of articular cartilage and associated inflammatory processes, which can lead to significant pain and disability. However, the heterogeneous nature of OA has limited the effectiveness of many anti-inflammatory interventions, highlighting the need for phenotype-driven therapeutic strategies. Methods: This narrative review was conducted by searching PubMed, Web of Science, and Google Scholar from inception to June 2025. Predefined keywords included "osteoarthritis", "inflammation", "pain", "synovitis", "effusion", "treatment", "therapy" and "clinical trials". Additional relevant publications were identified through citation tracking of the included papers. Results: Our analysis of recent randomized clinical trials (RCTs) reveals a clear divergence in therapeutic efficacy, while targeted biologics (eg, TNF-α inhibitors like adalimumab and IL-1 blockers such as lutikizumab) have largely failed to meet primary pain endpoints in unselected populations, broad-spectrum immunomodulators like methotrexate (MTX) show significant promise, particularly in reducing pain and stiffness for the inflammatory phenotype. Furthermore, emerging evidence suggests that intra-articular (IA) treatments and phenotype-driven stratifications are essential to overcoming the current "one-size-fits-all" failure in OA drug development. Conclusion: The central message of this review is that the inconsistent efficacy of anti-inflammatory therapies in OA reflects a patient-selection problem more than a failed target: agents tested in unselected populations, including most anti-cytokine biologics, have not relieved pain, whereas signals emerge for MTX in patients with an inflammatory phenotype. Stratifying patients by imaging-defined synovitis or effusion and inflammatory biomarkers is therefore the key unmet need, and phenotype-driven trial design-rather than new molecular targets alone-offers the most promising path to effective inflammation-targeted treatment of OA pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.